Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Open wound

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    130 result(s) found for: Open wound. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2017-002669-23 Sponsor Protocol Number: PROFITOP Start Date*: 2017-12-21
    Sponsor Name:Hospital General Universitari de Granollers
    Full Title: Prophylaxis of surgical wound infection with topical antibiotics
    Medical condition: Surgical wound infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10048038 Wound infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004383-22 Sponsor Protocol Number: Mikrodialyse Start Date*: 2013-05-13
    Sponsor Name:University of Leipzig
    Full Title: Perioperative complications in obese and non-obese patients: Prevention and treatment of wound infections and post-operative pain. Prospective, open, monocentric study to investigate perioperative...
    Medical condition: Prophylactic antibiotics, wound infections and pain associated with elective surgery in obese patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004863 10054711 Postoperative pain LLT
    14.1 10021881 - Infections and infestations 10036410 Postoperative wound infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000777-23 Sponsor Protocol Number: BSH-12 Start Date*: 2012-07-05
    Sponsor Name:Birken AG
    Full Title: Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in...
    Medical condition: Split-Thickness Skin Graft Donor Sites
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10041667 Split thickness skin graft LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FI (Completed) AT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003390-26 Sponsor Protocol Number: BSG-12 Start Date*: 2012-12-18
    Sponsor Name:Birken AG
    Full Title: Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in...
    Medical condition: Split-Thickness Skin Graft Donor Sites
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10041667 Split thickness skin graft LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019945-24 Sponsor Protocol Number: BEB-10 Start Date*: 2010-09-24
    Sponsor Name:Birken GmbH
    Full Title: Open, Prospective, Controlled Case series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare versus Non-adhesive Wound Dressing alone in Accelerating the Epitheliali...
    Medical condition: This is an open, prospective, controlled case-series documentation to compare intra-individually the efficacy and tolerance of Sericare versus standard treatment in accelerating the epithelializati...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005124-42 Sponsor Protocol Number: KEKLUKACS-CLIN-02 Start Date*: 2014-03-17
    Sponsor Name:Lukács és Társa Gyógyszerkereskedelmi Betéti Társaság
    Full Title: A Phase II/III Adaptive, Seamless, Prospective, Randomized, Controlled, Parallel, Open Multicenter Study to Assess the Safety and Efficacy of Kék Lukács Ointment Compared to Standard Silver Sulfadi...
    Medical condition: Partial thickness (second-degree) burns. Total study target burn area: > 25 cm2 < 400 cm2 (or 2% of TBSA), and the burn therapy begun within 6-72 hours.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-003066-24 Sponsor Protocol Number: MW2012-01-01 Start Date*: 2014-12-17
    Sponsor Name:MediWound Ltd.
    Full Title: A multicenter, multinational, randomized, controlled, open label study, performed in children with thermal burns, to evaluate the efficacy and safety of NexoBrid as compared to standard of care (SO...
    Medical condition: The study objective is to evaluate the safety and clinical benefit of NexoBrid in hospitalized children (0-18 years) with deep partial and/or full thickness thermal burns of 1-30% TBSA and to compa...
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004863 10043418 Thermal burns HLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) SK (Completed) DE (Completed) BE (Completed) AT (Prematurely Ended) BG (Prematurely Ended) NL (Prematurely Ended) FR (Completed) SE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017418-56 Sponsor Protocol Number: BSH-10 Start Date*: 2010-04-07
    Sponsor Name:Birken GmbH
    Full Title: Open, Prospective, Controlled, Randomised, Multicenter Phase II Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Moist Wound Healing Dressing alone in A...
    Medical condition: Es handelt sich um eine offene, prospektive, kontrollierte, randomisierte, multizentrische Studie der Phase II, die eine intra-individuelle Wirksamkeit und Verträglichkeit des Oleogel-S10 mit einer...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001466-25 Sponsor Protocol Number: MW2013-07-10 Start Date*: 2015-06-18
    Sponsor Name:MediWound, Ltd.
    Full Title: A multicenter, prospective, randomized, vehicle controlled, assessor blinded study performed in subjects with hard to heal wounds, to evaluate the efficacy and safety of enzymatic debridement with ...
    Medical condition: Hard to heal venous leg ulcers, diabetic lower extremity ulcers and traumatic/post operative wounds.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002066-32 Sponsor Protocol Number: BEB-13 Start Date*: 2017-11-10
    Sponsor Name:Amryt Research Limited
    Full Title: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow-up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa
    Medical condition: Inherited Epidermolysis Bullosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) AT (Completed) DE (Completed) ES (Ongoing) GR (Completed) HU (Completed) CZ (Completed) BE (Completed) DK (Completed) IT (Completed) HR (Completed) FR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-000362-38 Sponsor Protocol Number: BBW-11 Start Date*: 2012-06-18
    Sponsor Name:Birken AG
    Full Title: Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in...
    Medical condition: Superficial partial-thickness (grade 2a) burn wounds
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10006802 Burns second degree PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001374-34 Sponsor Protocol Number: 6630-0450-01 Start Date*: 2014-06-11
    Sponsor Name:MEDICE Arzneimittel Pütter GmbH & Co. KG
    Full Title: A monocentric, observer-blind, randomized clinical study using an abrasive wound model with an intra-individual comparison to investigate the wound healing properties of a topical wound healing pro...
    Medical condition: healthy volunteers; intended indication is the treatment of acute wounds such as abrasions, cuts, scratches, laceration, blistering burns and sunburns
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001815-21 Sponsor Protocol Number: ABH_EB-001 Start Date*: 2013-01-18
    Sponsor Name:Shire Regenerative Medicine, Inc.
    Full Title: A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with General...
    Medical condition: Epidermolysis bullosa
    Disease: Version SOC Term Classification Code Term Level
    15.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) AT (Completed) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004728-14 Sponsor Protocol Number: TCP25-001 Start Date*: 2022-03-10
    Sponsor Name:Xinnate AB
    Full Title: A Three-part, Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Topical Doses of TCP-25 in Healthy Male and Female Volunteers with Epidermal Suction Blister Wounds and in...
    Medical condition: TCP-25 gel targets both bacteria and inflammation, aspects common to many wounds and is being developed for a range of wound healing indications including prevention and treatment of infection and ...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005841-19 Sponsor Protocol Number: DT-DP-D3 Start Date*: 2013-10-10
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A Multicentric, Double Blind, randomised, Comparative Phase III Study of the Efficacy of the new Wound Healing Solution Diperoxochloric acid (DPOCL, DermaPro®) compared to isotonic Sodium Chloride ...
    Medical condition: Diabetic foot ulcers with mean diameter between 1.5 and 5 cm after débridement (if indicated); wound stage Wagner grade I or II, Armstrong stadium A or C (for Wagner-Armstrong-Classification), trea...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) LT (Completed) HU (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001392-32 Sponsor Protocol Number: SC-VLU-001 Start Date*: 2021-11-10
    Sponsor Name:SolasCure Ltd
    Full Title: An adaptive open label, multiple ascending dose study of the safety, tolerability and bio-effect of Aurase for wound debridement in patients with venous leg ulcers and diabetic foot ulcers (CLEANVL...
    Medical condition: Venous Leg Ulcer Diabetic Foot Ulcer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10066677 Chronic leg ulcer LLT
    24.0 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-004806-17 Sponsor Protocol Number: PQ-313-002 Start Date*: 2018-05-18
    Sponsor Name:Wings Therapeutics Inc.
    Full Title: A first in human, double-blind, randomized, intra-subject placebo-controlled, multiple dose study of QR-313 evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subj...
    Medical condition: Recessive Dystrophic Epidermolysis Bullosa (RDEB) due to mutation(s) in exon 73 of the COL7A1 gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005612-41 Sponsor Protocol Number: 15-15 Start Date*: 2015-11-30
    Sponsor Name:Meander Medical Centre
    Full Title: Vitamin c to Improve Tissue healing by Administration of Multiple INtravenous dosages
    Medical condition: Patients with planned revascularisation surgery on the lower extremities.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10003451 Ascorbic acid LLT
    18.1 10042613 - Surgical and medical procedures 10063919 Bypass surgery LLT
    18.1 10042613 - Surgical and medical procedures 10036892 Promotion of wound healing PT
    18.1 10042613 - Surgical and medical procedures 10061407 Vascular bypass graft LLT
    18.1 10042613 - Surgical and medical procedures 10053375 Peripheral revascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003890-91 Sponsor Protocol Number: BIOOPA Start Date*: 2020-09-29
    Sponsor Name:Medical University of Warsaw
    Full Title: The development of innovative advanced therapy medicinal product (biological dressing of the human race) in the treatment of Epidermolysis Bullosa (EB) and other chronic wounds.
    Medical condition: BIOOPA dressing will be used in the treatment of wounds in the course of Epidermolysis Bullosa, chronic venous leg ulceration and thermal injury (second degree burn).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023121-38 Sponsor Protocol Number: ICX-DEBRHY-2 Start Date*: 2011-01-13
    Sponsor Name:Intercytex Ltd
    Full Title: A prospective placebo controlled phase II study to evaluate the use of allogeneic fibroblasts for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa.
    Medical condition: Recessive dystropic epidermolysis bullosa
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 18:26:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA